The market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TRIB Stock dropped -2.50% Today — RQD Quant Desk Flash
Trinity Biotech plc (TRIB) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
⚔️ Adversarial Opposing Case: Why the TRIB Bull Thesis Could Fail
Even with a 56/100 (D+) score, TRIB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.69) or 200D SMA ($15.42) invalidates the momentum regime and cuts Target Base ($6.57) toward Bear Floor ($5.12).
Why TRIB Stock dropped -2.50% Today — RQD Quant Desk Flash
Trinity Biotech plc (TRIB) dropped -2.50% to $6.63, trading at 3% of its 52-week range ($5.01 – $52.5). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($5.01 – $52.5) with RSI-14 at 38.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.63 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $150950 annual free cash flow.
Haley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
Israeli strikes kill eight people in Gaza - medics say Reuters
Russia's FSB says minor detained over park attack threat after US tip-off Reuters
Iran, Qatari mediators hold third day of talks to end US-Iran war Reuters
Qatar surges, bucking Gulf market slide on Iran war concerns Reuters
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
German ministers pledge tough action after rioters damage stores in Frankfurt Reuters
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRIB)
- ✓Walkthrough of TRIB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
TRIB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TRIB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TRIB. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRIB)
1. Head-to-Head Health Care Peer Comparison (TRIB vs. CDIO, BMRA, QCLS, VRAX)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Trinity Biotech plc (TRIB) ranks #270 by composite RQD confidence (56/100, grade D+) and #940 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, TRIB leads on earnings valuation at N/A trailing P/E, while CDIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VRAX currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with TRIB at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRIB
ACTIVE
Trinity Biotech plc | D+ | 56/100 | — | — | — | -2.50% | $5.4M | Benchmark Subject |
| CDIO Cardio Diagnostics Holdings Inc. | E | 31/100 | — | — | -35.0% | +2.94% | $5.2M | /cdio-vs-trib → |
| BMRA Biomerica Inc. | D- | 39/100 | — | 8.1% | -35.0% | -0.57% | $8.0M | /bmra-vs-trib → |
| QCLS Q/C Technologies Inc. | D- | 42/100 | — | — | -35.0% | -3.44% | $3.6M | /qcls-vs-trib → |
| VRAX Virax Biolabs Group Limited | D+ | 58/100 | — | — | — | +10.00% | $1.8M | /vrax-vs-trib → |
2. TRIB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTTrinity Biotech plc (TRIB) operates in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. TRIB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TRIB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Trinity Biotech plc (NASDAQ: TRIB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $6.63 (-2.50% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TRIB ranks #270 in composite RQD confidence.
How does TRIB compare to CDIO and BMRA in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TRIB carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CDIO (Cardio Diagnostics Holdings Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and BMRA (Biomerica Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M). Among the 5-stock peer group, TRIB leads on earnings multiple (N/A) while CDIO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TRIB?
For Trinity Biotech plc (TRIB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #270 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TRIB trading relative to its 50-day, 200-day, and 52-week technical levels?
TRIB last traded at $6.63 (-2.50% on volume of 26,700 shares), positioning the stock -13.78% below its 50-day simple moving average ($7.69) and -57.00% below its 200-day simple moving average ($15.42). Across its 52-week range of $5.01 to $52.50, TRIB sits at the 3.4% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.80 to $7.46).
TRIB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TRIB stock moving today?
Why TRIB Stock dropped -2.50% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.